| Apimeds Pharmaceuticals US, Inc. (APUS) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | |
| Balance Sheet Date | 2026-Mar-31 | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | |||||||||||||||||||||||||||||||||||||||||||
| Fiscal Period | Q1-FY2026 | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | |||||||||||||||||||||||||||||||||||||||||||
| Operating Cash Flow | (2,067,727$) | (3,818,202$) | (1,726,166$) | (3,361,096$) | (20,313$) | (99,616$) | (186,755$) | (184,055$) | (263,100$) | ||||||||||||||||||||||||||||||||||||||||
| Investing Cash Flow | 490,606$ | (10,024,442$) | (22,540$) | ||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of Property and Equipment | 9,394$ | 21,424$ | 22,540$ | ||||||||||||||||||||||||||||||||||||||||||||||
| Financing Cash Flow | 920,000$ | 8,492,681$ | 0$ | 11,859,446$ | 267,200$ | 76,500$ | 150,000$ | ||||||||||||||||||||||||||||||||||||||||||
| End Cash Position | 979,534$ | 1,636,655$ | 6,986,617$ | 8,735,323$ | 250,432$ | 3,455$ | 26,571$ | 63,326$ | 147,381$ | 410,481$ | |||||||||||||||||||||||||||||||||||||||
| Exchange Rate Effect | |||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (2,077,121$) | (3,839,626$) | (1,748,706$) | (3,361,096$) | (20,313$) | (99,616$) | (186,755$) | (184,055$) | (263,100$) | ||||||||||||||||||||||||||||||||||||||||